{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:20:29Z","timestamp":1794270029691,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adding PD-1 blockade in the neoadjuvant regimens for locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) \/ mismatch repair-proficient (pMMR) tumors is an attractive, but debatable strategy. This phase 2, multicenter, prospective, single-arm study enrolled patients from 6 centers from June 2021 to November 2022. Locally advanced rectal cancer (LARC, cT<jats:sub>3-4a<\/jats:sub>N<jats:sub>0<\/jats:sub>M<jats:sub>0<\/jats:sub> and cT<jats:sub>1-4a<\/jats:sub>N<jats:sub>1-2<\/jats:sub>M<jats:sub>0<\/jats:sub>) patients aged \u226518 years with the distance from distal border of tumor to anal verge \u226410\u2009cm (identified by Magnetic Resonance Imaging) were qualified for inclusion. The patients received long-course radiotherapy (50\u2009Gy\/25 fractions, 2\u2009Gy\/fraction, 5 days\/week) and three 21-day cycles capecitabine (850\u20131000\u2009mg\/m2, bid, po, day1\u201314) and three 21-day cycles tislelizumab (200\u2009mg, iv.gtt, day8) as neoadjuvant. Total mesorectal excision (TME) was 6\u201312 weeks after the end of radiotherapy to achieve radical resection. A total of 50 patients were enrolled in this study. The pathological complete response rate was 40.0% [20\/50, 95% confidence interval (CI): 27.61\u201353.82%], while 15 (30.0%, 95% CI: 19.1\u201343.75%), 9 (18.0%, 95% CI: 9.77\u201330.8%), 2 (4.0%, 95% CI: 1.10\u201313.46%) patients respectively achieved grade 1, 2, and 3 tumor regression. Treatment-related adverse events (TRAEs) occurred in 28 (56.0%) LARC patients, including 26(52.0%) with grade I-II and 2 (4.0%) with grade III (1 with grade 3 immune-related colitis and 1 with grade 3 rash). PD-1 blockade plus long-course chemoradiotherapy (CRT) showed promising therapeutic effects according to pathological complete response rate and is well-tolerated in LARC patients. A larger randomized controlled study is desired to further validate the above findings.<\/jats:p>","DOI":"10.1038\/s41392-024-01762-y","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:03:41Z","timestamp":1710115421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study"],"prefix":"10.1038","volume":"9","author":[{"given":"Zhengyang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiagang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.14309\/ajg.0000000000000133","volume":"114","author":"JJY Sung","year":"2019","unstructured":"Sung, J. J. Y. et al. Increasing Trend in Young-Onset Colorectal Cancer in Asia: More Cancers in Men and More Rectal Cancers. Am. J. Gastroenterol. 114, 322\u2013329 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"1762_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.6004\/jnccn.2022.7061","volume":"20","author":"A Saraf","year":"2022","unstructured":"Saraf, A., Roberts, H. J., Wo, J. Y. & Parikh, A. R. Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location. J. Natl Compr. Cancer Netw. 20, 1177\u20131184 (2022).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1762_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2018.0037","volume":"16","author":"CG Willett","year":"2018","unstructured":"Willett, C. G. Management of Locoregional Rectal Cancer. J. Natl Compr. Canc Netw. 16, 617\u2013619 (2018).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1762_CR4","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","volume":"23","author":"JF Bosset","year":"2005","unstructured":"Bosset, J. F. et al. Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results\u2014EORTC 22921. JCO 23, 5620\u20135627 (2005).","journal-title":"JCO"},{"key":"1762_CR5","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP G\u00e9rard","year":"2006","unstructured":"G\u00e9rard, J. P. et al. Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. JCO 24, 4620\u20134625 (2006).","journal-title":"JCO"},{"key":"1762_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12957-022-02549-7","volume":"20","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Clinical benefits of PD-1\/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis. World J. Surg. Oncol. 20, 93 (2022).","journal-title":"World J. Surg. Oncol."},{"key":"1762_CR7","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen, L. et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. JCO 40, 3065\u20133076 (2022).","journal-title":"JCO"},{"key":"1762_CR8","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 Blockade in Mismatch Repair\u2013Deficient, Locally Advanced Rectal Cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1762_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu, H. et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 38\u201348 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1762_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2016.10.005","volume":"51","author":"F Gelsomino","year":"2016","unstructured":"Gelsomino, F., Barbolini, M., Spallanzani, A., Pugliese, G. & Cascinu, S. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treat. Rev. 51, 19\u201326 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"1762_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/jclinpath-2020-207281","volume":"74","author":"AC Bateman","year":"2021","unstructured":"Bateman, A. C. DNA mismatch repair proteins: scientific update and practical guide. J. Clin. Pathol. 74, 264\u2013268 (2021).","journal-title":"J. Clin. Pathol."},{"key":"1762_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma, O. E. et al. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 7, 1225 (2021).","journal-title":"JAMA Oncol."},{"key":"1762_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"1762_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2022.09.006","volume":"78","author":"M Kudo","year":"2023","unstructured":"Kudo, M. et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J. Hepatol. 78, 133\u2013141 (2023).","journal-title":"J. Hepatol."},{"key":"1762_CR15","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin. Cancer Res. 26, 1712\u20131724 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1762_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13046-022-02423-0","volume":"41","author":"C Baldini","year":"2022","unstructured":"Baldini, C. et al. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. J. Exp. Clin. Cancer Res. 41, 217 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1762_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer, A. et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 397, 592\u2013604 (2021).","journal-title":"Lancet"},{"key":"1762_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.eururo.2022.07.009","volume":"82","author":"BM De Ruiter","year":"2022","unstructured":"De Ruiter, B. M. et al. Phase 1 Study of Chemoradiotherapy Combined with Nivolumab \u00b1 Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. Eur. Urol. 82, 518\u2013526 (2022).","journal-title":"Eur. Urol."},{"key":"1762_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"1762_CR20","doi-asserted-by":"publisher","first-page":"638873","DOI":"10.3389\/fonc.2021.638873","volume":"11","author":"Y Kong","year":"2021","unstructured":"Kong, Y. et al. Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1\/PD-L1 Immunotherapy in Metastatic Cancers. Front Oncol. 11, 638873 (2021).","journal-title":"Front Oncol."},{"key":"1762_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejca.2017.11.005","volume":"89","author":"R Von Moos","year":"2018","unstructured":"Von Moos, R. et al. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I\/II trial (SAKK 41\/08). Eur. J. Cancer 89, 82\u201389 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1762_CR22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","volume":"28","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability\u2013High Locally Advanced Rectal Cancer. Clin. Cancer Res. 28, 1136\u20131146 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1762_CR23","doi-asserted-by":"publisher","first-page":"e003554","DOI":"10.1136\/jitc-2021-003554","volume":"9","author":"Z Lin","year":"2021","unstructured":"Lin, Z. et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J. Immunother. Cancer 9, e003554 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1762_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09554-9","volume":"22","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). BMC Cancer 22, 462 (2022).","journal-title":"BMC Cancer"},{"key":"1762_CR25","unstructured":"Amin, M. B. et al. AJCC cancer staging manual. (New York: Springer. 252\u2013274 2017)."},{"key":"1762_CR26","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2018 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (accessed May 3, 2018)."},{"key":"1762_CR27","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi, A. B., Lim, M., DeWeese, T. L. & Drake, C. G. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16, e498\u2013e509 (2015).","journal-title":"Lancet Oncol."},{"key":"1762_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27620-x","volume":"12","author":"YT Yen","year":"2021","unstructured":"Yen, Y. T. et al. Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nat. Commun. 12, 7297 (2021).","journal-title":"Nat. Commun."},{"key":"1762_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. Cancer Cell. 33, 547\u2013562 (2018).","journal-title":"Cancer Cell."},{"key":"1762_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"Diaz LA","year":"2022","unstructured":"Diaz LA et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659\u2013670 (2022).","journal-title":"Lancet Oncol."},{"key":"1762_CR31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2014.0099","volume":"12","author":"AB Benson","year":"2021","unstructured":"Benson, A. B. et al. Colon Cancer, Version 2.2021. J. Natl Compr. Canc Netw. 12, 1028\u20131059 (2021).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1762_CR32","doi-asserted-by":"publisher","first-page":"eaay0555","DOI":"10.1126\/sciimmunol.aay0555","volume":"4","author":"CG Kim","year":"2019","unstructured":"Kim, C. G. et al. VEGF-A drives TOX-dependent T cell exhaustion in anti\u2013PD-1\u2013resistant microsatellite stable colorectal cancers. Sci. Immunol. 4, eaay0555 (2019).","journal-title":"Sci. Immunol."},{"key":"1762_CR33","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1172\/JCI127046","volume":"129","author":"M Fakih","year":"2019","unstructured":"Fakih, M. et al. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J. Clin. Investig. 129, 4464\u20134476 (2019).","journal-title":"J. Clin. Investig."},{"key":"1762_CR34","doi-asserted-by":"publisher","first-page":"11014","DOI":"10.3390\/ijms231911014","volume":"23","author":"R Liu","year":"2022","unstructured":"Liu, R. et al. Infiltration of Apoptotic M2 Macrophage Subpopulation Is Negatively Correlated with the Immunotherapy Response in Colorectal Cancer. IJMS 23, 11014 (2022).","journal-title":"IJMS"},{"key":"1762_CR35","doi-asserted-by":"publisher","first-page":"1001444","DOI":"10.3389\/fimmu.2022.1001444","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. Current progress and future perspectives of neoadjuvant anti-PD-1\/PD-L1 therapy for colorectal cancer. Front Immunol. 13, 1001444 (2022).","journal-title":"Front Immunol."},{"key":"1762_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2022.02.032","volume":"77","author":"M Barsch","year":"2022","unstructured":"Barsch, M. et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J. Hepatol. 77, 397\u2013409 (2022).","journal-title":"J. Hepatol."},{"key":"1762_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495\u2013499 (2017).","journal-title":"Nature"},{"key":"1762_CR38","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","volume":"103","author":"WJ Curran","year":"2011","unstructured":"Curran, W. J. et al. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. JNCI J. Natl Cancer Inst. 103, 1452\u20131460 (2011).","journal-title":"JNCI J. Natl Cancer Inst."},{"key":"1762_CR39","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","volume":"20","author":"M Takada","year":"2002","unstructured":"Takada, M. et al. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. JCO 20, 3054\u20133060 (2002).","journal-title":"JCO"},{"key":"1762_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/jnccn.2015.0087","volume":"13","author":"AB Benson","year":"2022","unstructured":"Benson, A. B. et al. Rectal Cancer, Version 2.2022. J. Natl Compr. Canc Netw. 13, 719\u2013728 (2022).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1762_CR41","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 39, 1578\u20131593.e8 (2021).","journal-title":"Cancer Cell."},{"key":"1762_CR42","doi-asserted-by":"publisher","first-page":"e134569","DOI":"10.1172\/jci.insight.134569","volume":"5","author":"CE Gustafson","year":"2020","unstructured":"Gustafson, C. E. et al. Immune cell repertoires in breast cancer patients after adjuvant chemotherapy. JCI Insight 5, e134569 (2020).","journal-title":"JCI Insight"},{"key":"1762_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1762_CR44","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/bjs.8702","volume":"99","author":"ST Martin","year":"2012","unstructured":"Martin, S. T., Heneghan, H. M. & Winter, D. C. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br. J. Surg. 99, 918\u2013928 (2012).","journal-title":"Br. J. Surg."},{"key":"1762_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","volume":"11","author":"M Maas","year":"2010","unstructured":"Maas, M. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11, 835\u2013844 (2010).","journal-title":"Lancet Oncol."},{"key":"1762_CR46","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1200\/JCO.2013.54.3769","volume":"32","author":"E Fokas","year":"2014","unstructured":"Fokas, E. et al. Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO\/ARO\/AIO-94 Trial. JCO 32, 1554\u20131562 (2014).","journal-title":"JCO"},{"key":"1762_CR47","doi-asserted-by":"publisher","unstructured":"Organ preservation in rectal cancer: review of contemporary management. Br. J. Surg. Published online https:\/\/doi.org\/10.1093\/bjs\/znac140 (2022).","DOI":"10.1093\/bjs\/znac140"},{"key":"1762_CR48","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","volume":"29","author":"M Maas","year":"2011","unstructured":"Maas, M. et al. Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer. JCO 29, 4633\u20134640 (2011).","journal-title":"JCO"},{"key":"1762_CR49","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1097\/SLA.0b013e3182759f1c","volume":"256","author":"JD Smith","year":"2012","unstructured":"Smith, J. D. et al. Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy. Ann. Surg. 256, 965\u2013972 (2012).","journal-title":"Ann. Surg."},{"key":"1762_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1245\/s10434-014-3962-5","volume":"22","author":"JH Lee","year":"2015","unstructured":"Lee, J. H. et al. The Role of Fibrinogen as a Predictor in Preoperative Chemoradiation for Rectal Cancer. Ann. Surg. Oncol. 22, 209\u2013215 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"1762_CR51","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/cncr.22625","volume":"109","author":"P Das","year":"2007","unstructured":"Das, P. et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109, 1750\u20131755 (2007).","journal-title":"Cancer"},{"key":"1762_CR52","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00262-021-03056-6","volume":"71","author":"T Ugai","year":"2022","unstructured":"Ugai, T. et al. Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer. Cancer Immunol. Immunother. 71, 933\u2013942 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"1762_CR53","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/bjs\/znac298","volume":"109","author":"K Pang","year":"2022","unstructured":"Pang, K. et al. Adding immune checkpoint blockade to neoadjuvant chemoradiation in locally advanced rectal cancer. Br. J. Surg. 109, 1178\u20131179 (2022).","journal-title":"Br. J. Surg."},{"key":"1762_CR54","doi-asserted-by":"publisher","first-page":"1057947","DOI":"10.3389\/fonc.2023.1057947","volume":"13","author":"J Gao","year":"2023","unstructured":"Gao, J. et al. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer. Front Oncol. 13, 1057947 (2023).","journal-title":"Front Oncol."},{"key":"1762_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4132\/jptm.2019.09.28","volume":"54","author":"BH Kim","year":"2020","unstructured":"Kim, B. H. et al. Standardized Pathology Report for Colorectal Cancer, 2nd Edition. J. Pathol. Transl. Med. 54, 1\u201319 (2020).","journal-title":"J. Pathol. Transl. Med."},{"key":"1762_CR56","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S1470-2045(21)00053-X","volume":"22","author":"R Glynne-Jones","year":"2021","unstructured":"Glynne-Jones, R. & Glynne-Jones, S. The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer. Lancet Oncol. 22, e314\u2013e326 (2021).","journal-title":"Lancet Oncol."},{"key":"1762_CR57","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/annonc\/mdy143","volume":"29","author":"E Fokas","year":"2018","unstructured":"Fokas, E. et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO\/ARO\/AIO-04 randomized phase III trial. Ann. Oncol. 29, 1521\u20131527 (2018).","journal-title":"Ann. Oncol."},{"key":"1762_CR58","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S. et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. JCO 34, 1510\u20131517 (2016).","journal-title":"JCO"},{"key":"1762_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).","journal-title":"J. Immunother. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01762-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:04:01Z","timestamp":1710115441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-01762-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}